- US-listed companies
- Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc.ANEB
Market cap
$51.87M
P/E ratio
Jun 30, 2021 | Jun 30, 2022 | Jun 30, 2023 | |
Research and development | 2 | 3 | 6 |
General and administrative | 1 | 4 | 6 |
Total operating expenses | 4 | 7 | 12 |
Loss from operations | - | -6,831,174 | -11,783,599 |
Interest income | - | 7,332 | 92,407 |
Other | -1,344 | -1,777 | -41,146 |
Total other income, net | -26,638,801 | 5,555 | 51,261 |
Net loss | -30,252,554 | -6,825,619 | -11,732,338 |
Net loss per share, basic | - | -0.29 | 0.47 |
Net loss per share, diluted | - | - | 0.47 |